Are there alternatives to Platinib?

Pralsetinib (Pralsetinib) is a receptor tyrosine kinase RET (Rearranged during Transfection) inhibitor , mainly used for the treatment of adult patients with advanced RET fusion-positive non-small cell lung cancer, as well as systemic treatment of adult and pediatric patients 12 years and older with advanced or metastatic transfection rearrangement (RET) mutant medullary thyroid carcinoma (MTC) and transfection rearrangement (RET) fusion-positive thyroid cancer (TC). Currently, the price of platinib sold in China is relatively high, with a box of approximately RMB 20,000 to RMB 60,000. Therefore, some patients may seek alternative medications to reduce financial burden.

As for alternatives to platinib, there are currently some other drugs on the marketRET Inhibitors, such as nivolumab (Nivolumab), Pembrolizumab (Pembrolizumab) span>, selpercatinib (selpercatinib), cabozantinib (cabozantinib), etc. This class of tyrosine kinase inhibitors works by inhibiting a variety of tyrosine kinases, enzymes that promote tumor growth and angiogenesis (the formation of new blood vessels that feed tumors). By blocking these pathways, tumor growth and spread can be reduced. Although these drugs can control the disease and extend progression-free survival, they are not considered a cure for cancer. Different drugs may have different mechanisms of action and indications. Therefore, when choosing alternative drugs, decisions need to be made based on the patient's specific situation and the doctor's recommendations.

In addition, when using platinib or other drugs, you also need to pay attention to the adverse reactions and side effects of the drugs. For example, Platinib may cause adverse reactions such as hypertension, interstitial lung disease/non-infectious pneumonia, and poor wound healing. Therefore, when using these drugs, patients need to receive regular evaluation and guidance from doctors, and adjust the drug dosage or change drugs in a timely manner to avoid the occurrence of adverse reactions.